AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04522128 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behaviour Change Technique Intervention to Improve Quality of Life
Description: The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group.
Study NCT01008605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: delivery system
Description: syringe
Study NCT03578224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)
Description: Undergo EUS-FNA
Study NCT03578224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS
Study NCT03578224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration
Description: Undergo FNA
Study NCT03578224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid (Perflubutane)
Description: Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
Study NCT03687554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat GZ/SAR402671
Description: Pharmaceutical form: Hard Capsule Route of administration: Oral
Study NCT03997812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 1000 mg of VVZ-149
Study NCT03997812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study NCT04594681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered once daily or three times daily.
Study NCT04594681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4951
Description: KHK4951 is administered once daily or three times daily.
Study NCT03918629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile
Description: Toxoid-based Clostridium difficile vaccine
Study NCT03470337 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02953899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
Study NCT02158845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS: levonorgestrel intrauterine system
Description: LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
Study NCT02158845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa: leuprolide
Description: 3.75 mg leuprolide injected intramuscularly on a monthly basis
Study NCT03918629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline solution (0.9% sodium chloride)
Study NCT02862002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic education of type caratif
Description: study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology
Study NCT02862002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic education of type caratif
Description: study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology
Study NCT01324778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed TX
Description: OsseoSpeedTM TX implants of lengths 6-17 mm
Study NCT02862002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: patients receiving standard care of cancer pain.
Study NCT02862002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: patients receiving standard care of cancer pain.
Study NCT03592251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive Oil Placebo
Description: 6 months placebo supplementation
Study NCT02953899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
Study NCT01324778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsseoSpeed
Description: OsseoSpeedTM implants of lengths 6-17 mm
Study NCT03592251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-rich
Description: 6 months placebo supplementation
Study NCT03592251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA-rich
Description: 6 months placebo supplementation
Study NCT03592251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich
Description: 6 months placebo supplementation
Study NCT03592251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DHA-rich
Description: 6 months placebo supplementation
Study NCT02756182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDOC air-charged catheter
Description: Urodynamic study utilizing a single catheter technique to measure WP \& AC measurements
Study NCT04570033 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism
Description: We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
Study NCT05003765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
Study NCT05003765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg
Description: Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
Study NCT05003765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg
Description: Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
Study NCT01723358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
Study NCT03990012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IR Imaging
Description: Subjects will undergo steady steady state and video IR imaging of the breasts.
Study NCT03990012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Scanning
Description: Subjects will undergo 3D scanning of the breasts.
Study NCT02433015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
Study NCT02433015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cigarette
Description: Smoke own brand of cigarette as previously
Study NCT02248272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 3 meals
Description: Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
Study NCT02248272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 6 meals
Description: Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: 3 ug/kg on Day 1, IV over 15 minutes
Study NCT00329706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET brain scan
Description: The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
Study NCT00329706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET brain scan
Description: The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
Study NCT03377712 — intervention group
Intervention type: DEVICE
Intervention: optoelectronic plethysmography
Description: Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
Study NCT03377712 — intervention group
Intervention type: DEVICE
Intervention: diaphragmatic ultrasound
Description: Evaluates the diaphragmatic mobility through images, simple and non-invasive use
Study NCT01927120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
Study NCT01927120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Study NCT01927120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Orally on day -1. The dose for loading is 12 mg by mouth (PO)
Study NCT01437293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa / carbidopa / entacapone (LCE)
Description: For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
Study NCT04133857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
Study NCT01930682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
Study NCT01930682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early post-fibrinolytic catheterisation
Description: Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
Study NCT01930682 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary PCI
Description: For STEMI Patients,primary PCI is performed within 12 hours after the onset.
Study NCT01424007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
Study NCT03642197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attendance
Description: The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
Study NCT00870844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
Study NCT00870844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vials with solution for IV infusion
Study NCT00469924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Time Clinical Alerting
Study NCT04720105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duobrii®
Description: Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
Study NCT03500198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery.
Study NCT03500198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery.
Study NCT05271175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active intermittent theta burst stimulation
Description: An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.
Study NCT05271175 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intermittent theta burst stimulation
Description: An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil. The MagVenture Cool-B65 Active/Placebo (A/P) coil is designed to support true double blinded clinical trials as it can produce active and placebo stimulation by flipping the coil and can mimic tapping sensation during placebo condition During the sham condition, the coil produced the same sound as the real active condition but did not deliver any stimulation on the side of the participant's skull.
Study NCT01060241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
Study NCT02279966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Study NCT02279966 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paroxetine 20 mg
Study NCT02279966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04459039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mL 0.9% sterile saline
Description: Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
Study NCT04459039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 250 mL 0.9% sterile saline
Description: Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
Study NCT01891864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2015 Etanercept
Description: Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
Study NCT01891864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Description: Enbrel is used as reference product to GP2015.
Study NCT03593837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huang qi gui zhi wu wu granule
Description: Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
Study NCT03593837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huang qi gui zhi wu wu granule placebo
Description: Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
Study NCT01092130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000 IU vitamin D daily, for 6 weeks
Study NCT01616992 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine
Description: 20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2, on Day 2, IV over 2 hours
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m\^2, on Day 2, IV over 2 hours
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2, on Day 2, IV over 2 hours
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m\^2, on Day 2, IV over 2 hours
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2, on Day 2, IV over 1.5 hours
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m\^2, on Day 2, IV over 1.5 hours
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 2,400 mg/m\^2, Days 2-4, IV over 46 hours
Study NCT01959139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 2,400 mg/m\^2, Days 2-4, IV over 46 hours
Study NCT01900587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER Tamper-resistant Formulation (TRF)
Description: Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
Study NCT01900587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER Prolonged-Release 2 (PR2)
Description: Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
Study NCT01819896 — intervention group
Intervention type: DRUG
Intervention: Pacemaker and defibrillator
Study NCT02173171 — intervention group
Intervention type: OTHER
Intervention: Information collection
Description: Q3M Information collection
Study NCT03154996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)
Study NCT03154996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
Study NCT03154996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchromed II infusion pumps
Description: Implanted subcutaneously to facilitate chronic infusion.
Study NCT02270554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo GIA Reinforced Reload with Tri-Staple technology
Description: Device:Endo GIA Reinforced Reload with Tri-Staple technology